Patheon: Contract Manufacturing on Three-to-Five-Year TermsNarrow moat

Thermo Fisher Scientific (TMO) — moat facet

Once a drug is approved to be made in a Thermo Fisher plant, moving it means new regulatory filings, which is why contract manufacturing contracts run for years.

Thermo Fisher manufactures drugs for pharmaceutical companies, a business it bought as Patheon on 29 August 20171 for $7,358 million2. It has added to it since: Brammer Bio for $1,674 million in 2019 and a European viral vector business for $830 million in 20213, and a sterile fill-finish site bought from Sanofi in Ridgefield, New Jersey4.

Contract manufacturing purchases ($M)Patheon 20177,358Brammer Bio 20191,674European viral vector 2021830Thermo Fisher Forms 10-K FY2017 and FY2021
A manufacturing business assembled by acquisition.

The business is large and growing again. Pharma services revenue was $6,806 million in 2023, $6,685 million in 2024 and $7,142 million in 20255, when it grew by $457 million6. In the second quarter of 2026 it was $1,893 million against $1,794 million7.

Contract manufacturing has a natural lock. Once a drug is approved with a named manufacturing site, moving production means new regulatory filings. The 10-K says contracts of this kind "typically have durations of three to five years"8.

The cost is capital. The segment that holds pharma services spent $1,005 million on property, plant and equipment in 20259.

Patheon was paid for largely in cash: $6,861 million, plus $488 million of debt assumed10. The segment that now holds it had assets of $6,485 million at the end of 202511, the most of the four segments, because making drugs for others needs plants. That is the capital this facet of the moat has to earn a return on.

The facet would weaken if pharma services revenue fell for a year while capital spending stayed high. Quarterly revenue of $1,893 million is the current level.

Moat trajectory: Widening

Pharma services $6,685M (2024) to $7,142M (2025).

The number that tests this moat
Reported
Pharma services revenue, latest quarter
$1,893M, against $1,794M (Q2 2026)

Contract manufacturing; a year of decline while capital spending stays high would undercut it.

Source: Thermo Fisher Form 10-Q, Q2 2026 ↗
⚠ Threats to the moat
⚠ THREAT 01
Two-Thirds of Capital Spending Goes to a 14% Segment
Two-thirds of Thermo Fisher's capital spending goes to its lowest-margin segment, because factories for other people's drugs need concrete.
References
  1. ReportedThermo Fisher manufactures drugs for pharmaceutical companies, a business it bought as Patheon on 29 August 2017 for $7,358 million.
    Thermo Fisher Scientific Form 10-K for fiscal 2017 - segment revenue and income for 2015-2017, net income and EPS, service revenue, headcount and the FEI, Affymetrix and Patheon acquisitions. — FY2017 · publ. February 2018 · source ↗
  2. ReportedThermo Fisher manufactures drugs for pharmaceutical companies, a business it bought as Patheon on 29 August 2017 for $7,358 million.
    Thermo Fisher Scientific Form 10-K for fiscal 2017 - segment revenue and income for 2015-2017, net income and EPS, service revenue, headcount and the FEI, Affymetrix and Patheon acquisitions. — FY2017 · publ. February 2018 · source ↗
  3. ReportedIt has added to it since: Brammer Bio for $1,674 million in 2019 and a European viral vector business for $830 million in 2021, and a sterile fill-finish site bought from Sanofi in Ridgefield, New Jersey.
    Thermo Fisher Scientific Form 10-K for fiscal 2021 - the PPD, PeproTech, Brammer Bio, European viral vector and Mesa Biotech acquisitions, the Anatomical Pathology sale, COVID-19 response revenue, headcount and remaining performance obligations. — FY2021 · publ. February 2022 · source ↗
  4. ReportedIt has added to it since: Brammer Bio for $1,674 million in 2019 and a European viral vector business for $830 million in 2021, and a sterile fill-finish site bought from Sanofi in Ridgefield, New Jersey.
    Thermo Fisher Scientific fourth-quarter and full-year 2025 results, Form 8-K exhibit 99.1 - adjusted EPS, free cash flow, capital deployment, the Accelerator offering and the OpenAI collaboration. — FY2025 · publ. 29 January 2026 · source ↗
  5. ReportedPharma services revenue was $6,806 million in 2023, $6,685 million in 2024 and $7,142 million in 2025, when it grew by $457 million.
    Thermo Fisher Scientific Form 10-K for fiscal 2025 - revenue by business. — FY2025 · publ. 26 February 2026 · source ↗
  6. ReportedPharma services revenue was $6,806 million in 2023, $6,685 million in 2024 and $7,142 million in 2025, when it grew by $457 million.
    Thermo Fisher Scientific Form 10-K for fiscal 2025 - revenue by business. — FY2025 · publ. 26 February 2026 · source ↗
  7. ReportedIn the second quarter of 2026 it was $1,893 million against $1,794 million.
    Thermo Fisher Scientific Form 10-Q for the quarter ended 27 June 2026 - revenue by business and by type, the Clario purchase price, the microbiology sale, share repurchases, dividends and the balance sheet. — Q2 2026 · publ. 31 July 2026 · source ↗
  8. ReportedThe 10-K says contracts of this kind "typically have durations of three to five years".
    Thermo Fisher Scientific Form 10-K for fiscal 2025 - Item 1 business, executive officers, employees and remaining performance obligations. — FY2025 · publ. 26 February 2026 · source ↗
  9. ReportedThe segment that holds pharma services spent $1,005 million on property, plant and equipment in 2025.
    Thermo Fisher Scientific Form 10-K for fiscal 2025 - revenue by business. — FY2025 · publ. 26 February 2026 · source ↗
  10. ReportedPatheon was paid for largely in cash: $6,861 million, plus $488 million of debt assumed.
    Thermo Fisher Scientific Form 10-K for fiscal 2017 - segment revenue and income for 2015-2017, net income and EPS, service revenue, headcount and the FEI, Affymetrix and Patheon acquisitions. — FY2017 · publ. February 2018 · source ↗
  11. ReportedThe segment that now holds it had assets of $6,485 million at the end of 2025, the most of the four segments, because making drugs for others needs plants.
    Thermo Fisher Scientific Form 10-K for fiscal 2025 - segment information: revenue, income, margins, assets and capital spending. — FY2025 · publ. 26 February 2026 · source ↗
Sources
Generated September 28, 2026